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Background: POEMS syndrome is a plasma cell disorder manifested by Polyneuropathy, Organo-
megaly, Endocrinopathy, Monoclonal gammopathy and Skin changes. Pulmonary morbidity in-
cludes restriction, decreased diffusing capacity for carbon monoxide (DLCO), respiratory
muscle weakness, abnormal imaging, and pulmonary hypertension. Autologous peripheral
blood stem cell transplantation (aPBSCT) is an effective treatment for POEMS syndrome. It
is unknown if aPBSCT improves pulmonary morbidity. We hypothesize pulmonary morbidity will
improve following aPBSCT.
Methods: Retrospective cohort study of POEMS syndrome aPBSCT recipients from 2000 to 2010.
Demographic, pulmonary function test (PFT), echocardiogram, cytokine, and imaging data at
baseline and after aPBSCT were abstracted. Pre- and post-transplant data were compared us-
ing Wilcoxon signed-rank and McNemar’s tests.
Results: 53 patients met criteria. Median improvements in forced expiratory volume in 1 s
(FEV1), forced vital capacity (FVC), and total lung capacity (TLC) after transplant were 180,
315 and 350 ml respectively (median follow-up of 1.1 years). DLCO, maximal inspiratory pres-
sure (MIP), and maximal expiratory pressure (MEP) improved by a median of 11, 12.5 and 10%
predicted respectively. RVSP and chest imaging also improved. Vascular endothelial growthulmonary and Critical Care Medicine, Mayo Clinic, Gonda 18S, 200 1st St. SW, Rochester, MN 55905.
6 4372.
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aPBSCT Autologous peripheral
transplantation
CT Computed tomography
CXR Chest x-ray
DLCO Diffusing capacity for
ECHO Echocardiogram
FEV1 Forced expiratory volu
FVC Forced vital capacity
HB Hemoglobin
ICU Intensive care unit
IL-6 Interleukin 6factor and IL-6 decreased by a median of 334 and 2 pg/ml respectively. All comparisons were
statistically significant. Longitudinal data demonstrated stability in FEV1, MEP, and TLC and
continued improvement in FVC, MIP and DLCO on subsequent PFTs (median follow-up 26.5
months).
Conclusion: Patients with POEMS syndrome treated with aPBSCT have significant improvement
in PFTs, respiratory muscle strength, imaging, and post-transplant IL-6. The improvement in
PFTs persists during long-term follow-up.
ª 2014 Elsevier Ltd. All rights reserved.blood stem cell
carbon monoxide
me in 1 s
IQR Interquartile range
LVEF Left ventricular ejection function
MEP Maximum expiratory pressure
MIP Maximum inspiratory pressure
PFT Pulmonary function test
POEMS Polyneuropathy, Organomegaly,
Endocrinopathy, Monoclonal gammopathy and
Skin changes
RV Residual volume
RVSP Right ventricular systolic pressure
TLC Total lung capacity
VEGF Vascular Endothelial Growth FactorIntroduction
POEMS syndrome is a plasma cell dyscrasia associated with
significant pulmonary morbidity. Pulmonary manifestations
are common including pulmonary restriction, decreased
diffusing capacity of the lung for carbon monoxide (DLCO),
respiratory muscle weakness and pulmonary hypertension
[1,2]. In addition cough, respiratory muscle weakness, and
pulmonary hypertension are associated with decreased
median survival in POEMS syndrome [1,3]. Cardiorespiratory
failure is the most common cause of death [4,5]. Therefore
POEMS syndrome is an important systemic disease to pul-
monologists, cardiologists, and intensivists.
Autologous peripheral blood stem cell transplantation
(aPBSCT) is an effective treatment for the plasma cell
dyscrasia [6]. However, poor pulmonary function is often
considered a relative contraindication to aPBSCT. Thus
POEMS patients with pulmonary morbidity are at risk for
exclusion from this effective treatment. Interestingly,
improvement in PFTs has been reported in three patients
following aPBSCT for POEMS syndrome [7]. In addition,
POEMS syndrome-associated pulmonary hypertension has
been reported to respond to treatment [8e10]. It is un-
known if reversibility of pulmonary morbidity in POEMS
syndrome patients is a consistent finding. Understanding
whether POEMS syndrome associated-pulmonary hyperten-
sion and/or abnormal pulmonary function tests are
reversible, or not, would assist clinicians weighing the risks
and benefits of aPBSCT.
It is also unknown what causes pulmonary hypertension
in POEMS syndrome. Cytokines such as vascular endothelial
growth factor (VEGF) and interleukin-6 (IL-6) have beenpostulated to play a role in pulmonary hypertension in this
disorder [11e13]. Interestingly, VEGF has been demon-
strated to decrease following aPBSCT [6]. A careful exam-
ination of IL-6 pre-and post-aPBSCT would be helpful to
refute or endorse the hypothesized association between
POEMS-associated pulmonary hypertension and elevated
cytokines.
In this retrospective cohort study, we compare pre-
aPBSCT and post-aPBSCT pulmonary function, echocardio-
gram, imaging and cytokine data to investigate whether
aPBSCT impacts pulmonary manifestations of POEMS syn-
drome and whether pulmonary hypertension is associated
with cytokine elevation. Some of the results have been
previously reported in an abstract form [14]. This manu-
script represents a focused analysis of pulmonary morbidity
in a previously described cohort. [6].
Materials and methods
Patient selection
This is a single-center, retrospective cohort study of all
research consenting patients with POEMS syndrome who
underwent autologous peripheral blood stem cell trans-
plantation (aPBSCT) between 01/01/2000 and 07/31/2010
at our institution. Six patients with POEMS syndrome who
were followed after receiving aPBSCT elsewhere were
excluded (due to lack of baseline and aPBSCT data). The
study was approved by Institutional Review Board of Mayo
Clinic (IRB 2469-03). POEMS syndrome was diagnosed ac-
cording to established diagnostic criteria [4,15]. In brief, a
diagnosis of POEMS syndrome requires presence of
Table 1 Baseline characteristics.
Characteristics N (%) unless indicated
Male 33 (62)
Age, Median (IQR) 51 (41e58)
Race
White 40 (75)
African-American 6 (11)
Nonsmokers 33 (62)
Comorbidities
Preexisting pulmonary disease 2 (4)
Congestive heart failure 1 (2)
BMI, Median (IQR) 26 kg/m2 (22.8e30)
POEMS manifestations
Polyneuropathy 51 (96.2)
Organomegaly 35 (67.3)
Endocrinopathy 48 (90.6)
Monoclonal gammopathy 52 (98.1)
Skin manifestations 50 (94.3)
Castleman variant 11 (20.8)
Extravascular fluid overload 49 (92.5)
Hemoglobin, Median (IQR) 11.8 g/dL (10.3e12.9)
*Values in parenthesis represent percentage. IQRZ interquartile
range; BMI Z body mass index.
124 S. Chandrashekaran et al.polyneuropathy, a plasma cell disorder, and either sclerotic
bone lesions, Castleman disease, or elevated VEGF with at
least one other minor criteria (organomegaly, endocrinop-
athy, skin manifestations, papilledema, thrombocytosis, or
edema).
Autologous stem cell practice
Adult patients considered for autologous stem cell trans-
plant at our institution are generally expected to have an
Eastern Cooperative Oncology Group (ECOG) performance
status of 0e2, a left ventricular ejection fraction of >40%,
a forced expiratory volume in 1 s (FEV1) and DLCO >50%
although exceptions occur on a case-by-case basis [16]. The
ECOG performance status eligibility criterion was waived in
these patients since many had reduced performance status
due to severe peripheral neuropathy. Those patients with
the worst PFTs received attenuated dose of melphalan
conditioning pre-aPBSCT.
Data collection
Demographic data, presence of pre-existing lung or heart
disease, smoking history, radiologic imaging, pulmonary
function tests (PFT), echocardiogram (ECHO), weight, and
laboratory values of IL-6 and VEGF were abstracted before
and three or more months after transplant. When multiple
values were available, the data immediately pre-transplant
and the data closest to (but no earlier than) three months
post-aPBSCT were used for the post-transplant data. A
second post-aPBSCT PFT was abstracted if available before
November 15, 2012.
Pulmonary function test
All pulmonary function tests were performed according to
national practice guideline standards for repeatability and
acceptability. [17e20].
Echocardiography
All transthoracic echocardiographies were performed in
accordance with national practice guidelines [21,22]. The
right ventricular systolic pressure (RVSP) was calculated
using the tricuspid valve systolic regurgitant jet velocity.
[23].
Definitions
Smoking history was recorded as the number of years of
smoking multiplied by the number of packs per day (pack
years). Predicted normal values for PFTs were calculated
using a standardized database [24,25]. FEV1, forced vital
capacity (FVC), and DLCO were considered abnormal if less
than 80% predicted normal values. DLCO was adjusted for
hemoglobin whenever possible. Maximal inspiratory (MIP)
and expiratory pressures (MEP) were defined as abnormal if
either was less than 70% of predicted normal values. Total
lung capacity (TLC) was considered abnormal if less than
80% or greater than 120% predicted normal value. Residualvolume (RV) and RV/TLC were considered abnormal if
greater than 130% predicted. Left ventricular ejection
fraction (LVEF) less than 55% was considered abnormal.
Pulmonary hypertension was estimated by the RVSP with an
RVSP greater than 35 mmHg considered abnormal (given a
normal LVEF). Plasma IL-6 and VEGF levels were considered
abnormal if >5 pg/mL and >86 pg/mL, respectively.
Data analysis
Categorical variables were summarized with frequencies
and percentages and continuous variables were summa-
rized using medians and interquartile ranges (IQR). Data
analysis was performed using Wilcoxon signed-rank and
McNemar’s tests where appropriate (JMP, version 8.0; SAS
Institute Inc; Cary, NC). Any p-value less than 0.05 was
considered statistical significant.
Results
Demographics
Patient characteristics are summarized in Table 1. Fifty-
three patients were included. Thirty-eight percent were
current or former smokers with an average smoking history
of 23.6 pack-years. One patient each had pre-existing
chronic obstructive pulmonary disease, asthma or conges-
tive heart failure. Twenty-nine percent of the patients with
elevated baseline IL-6 (N Z 9/31) had Castleman disease.
Test measurements
Patients demonstrated statistically significant improve-
ments in PFTs (other than residual volume), RVSP, and
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interval between the pulmonary function tests was 1.1
years with a narrow IQR of 0.9e1.2 years. The overall me-
dian value increased for FEV1 (6% or 180 ml; N Z 38), FVC
(6.5% or 315 ml; N Z 38), and TLC (5% or 350 ml; N Z 27).
Similarly the median percent predicted increased for MIP
(12.5%; N Z 30) and MEP (10%; N Z 29). RV/TLC was
significantly smaller following aPBSCT (median decrease of
7%; N Z 27) consistent with the observed improvements in
maximal respiratory pressures. However residual volume
did not demonstrate a statistically significant difference
(p Z 0.33; N Z 27) following aPBSCT suggesting the
improvement in RV/TLC was secondary to the observed
increases in the TLC. DLCO was able to be adjusted for
hemoglobin in 96% of baseline and 81.7% of subsequent
DLCO measurements limiting confounding by anemia. DLCO
also significantly improved, although the median improve-
ment was small (median of 11% or 2.6 gm/dL; NZ 38). The
subset of patients abnormal at baseline demonstrated
larger median improvements FVC (10% or 360 ml), TLC (8%
or 540 ml), DLCO (15%), MIP (23%), MEP (15%), and RV/TLC
(decrease of 12%) following aPBSCT (Table 3). The subset of
patients with an abnormal RV at baseline was small; the
abnormal RVs at baseline did not demonstrate significant
improvement following aPBSCT.
Although the number of patients with repeat ECHO was
small, the RVSP likewise demonstrated small but significant
improvement following transplant (median decrease ofTable 2 Changes in test parameters in POEMS patients followin
Parameter Pre-aPBSCT
median (IQR)
Post-aPBSCT
median (IQR
FEV1% predicted
Value in liters
80 (66.5e92)
2.71 (2.07e3.46)
88 (77.5e
2.89 (2.35e3
FVC % predicted
Value in liters
84 (70e96)
3.61 (2.55e4.55)
93 (78.75
3.82 (3.16e4
TLC % predicted
Value in liters
88 (75.5e97)
5.52 (4.45e6.39)
98.5 (89.25
6.05 (5.1e6.
DLCO % predicted 64 (54.5e73.5) 80.50 (69e8
MIP % predicted 75 (65e85) 84 (74.5e
MEP % predicted 53 (46e72) 72 (60.25
RV % predicted 103 (94e121) 117.5 (95.8e
RV/TLC % predicted 121 (105e139) 117.5 (101.5
RVSP mmHg
% change
36 (32e45.5) 35 (31e3
VEGF pg/ml
% change
420.5 (147.75e693.5) 56 (33e9
IL-6 pg/ml
% change
5.07 (3.44e7.05) 3.025 (1.51e
Weight (kg)
% change
77.7 (67.3e91.55) 77.65 (63.4e
Hb, g/dL
% change
11.8 g/dL (10.3e12.9) 12.5 (1.3e1
POEMS Z polyneuropathy, organomegaly, endocrinopathy, monoclo
aPBSCTZ autologous peripheral blood stem cell transplantation; FEV
TLC Z total lung capacity; DLCO Z diffusion capacity of the lun
MEP Z maximum expiratory pressure; RV Z residual volume; RVSP Z
growth factor; IL-6 Z interleukin-6; Hb Z hemoglobin.7 mm Hg; NZ 13). In addition, the cytokines VEGF and IL-6
decreased post-aPBSCT by a median of 334 (N Z 31) and
2.04 pg/ml (N Z 18) respectively (see Table 2).Longitudinal PFT data
A second post-aPBSCT PFT was abstracted if available
before November 15, 2012 in order to determine if
observed PFT changes were persistent and whether
continued late improvement occurred (see Table 4). Thirty-
two patients had further pulmonary function test follow-up
(median follow-up of 26.5 months with IQR 24e33 months).
FEV1 did not demonstrate significant change between initial
post-aPBSCT and subsequent measure (pZ 0.076; NZ 32).
Likewise subsequent TLC and MEP measurements did not
demonstrate significant change (p Z 0.72; N Z 29 and
p Z 0.08; N Z 27 respectively). This suggests observed
initial improvements in FEV1, TLC and MEP are persistent
but that further improvement does not occur. Interestingly,
FVC demonstrated continued small but significant
improvement with a median increase of 1.5% and IQR -1 to
5.75% (p Z 0.03; N Z 32). DLCO also continued to
demonstrate small improvement on subsequent testing
with a median improvement of 4% and IQR 0.25e11%
(p Z 0.0006; N Z 32). MIP likewise continued to demon-
strate significant improvement with a median increase of
6% predicted with IQR -8 to 19% (p Z 0.034; N Z 27).g autologous peripheral blood stem cell transplantation.
)
Median difference pre
vs post-aPBSCT (IQR)
Wilcoxon signed
rank test p-value
97)
.81)
6 (1e13.25)
0.180 (0.0325e0.4025)
p < 0.001
e102.25)
.80)
6.5 (0.75e13.5)
0.315 (0.04e0.49)
p < 0.001
e107)
98)
5 (2e15)
0.350 (0.14e0.77)
p < 0.001
6.25) 11(3e20.25) p < 0.001
104) 12.5(-2-24.5) p Z 0.006
e80.25) 10 (0.5-18.5) p Z 0.021
129) 1 (9 to 14) p Z 0.33
e131.5) 7 (15 to 3) p Z 0.01
9) 7 (27 to 3)
19.4%
p < 0.001
6) 334 (415to 114)
79.4%
p < 0.001
4.55) 2.04 (4.71 to 0.47)
40.2%
p Z 0.015
90.75) 1.2 (4.2e2.5)
1.5%
p Z 0.22
3.6) 0.6 g/dL
5.1%
p < 0.001
nal gammopathy and skin changes; IQR Z interquartile range;
1Z forced expiratory volume in 1 s; FVCZ forced vital capacity;
g for carbon monoxide; MIP Z maximum inspiratory pressure;
right ventricular systolic pressure; VEGF Z vascular endothelial
Table 3 Changes in test parameters in POEMS patients following autologous peripheral blood stem cell transplantation.
Parameter Proportion of
abnormal baseline
test (%)
Absolute median improvement
in patients with abnormal
baseline test (IQR)
Wilcoxon signed rank
test p-value
FEV1% predicted
value in liters
25/53 (47%) 6 (1e13.25)
0.180 (0.07e0.345)
p Z 0.004
FVC % predicted
value in liters
21/53 (40%) 10 (3e16)
0.360 (0.195e0.497)
p Z 0.010
TLC %
value in liters
12/41 (29.26%) 8 (4e17)
0.54 (0.23e0.9)
p Z 0.016
DLCO % 42/53 (79%) 15 (4.5e21.75) p Z 0.001
MIP % 15/39 (38.46%) 23 (2 e 33) p Z 0.012
MEP % 28/39 (72%) 15 (6.75e22.25) p Z 0.001
RV % 8/41 (19.5%) 0 (15.75e8.25) p Z 0.6
RV/TLC% 16/41 (39%) 12 (3 to 19) p Z 0.0053
RVSP mmHg 26/45(58%) 8 (28 to 4) p Z 0.001
VEGF pg/ml 32/36(89%) 374 (551.5 to 157.5) p Z 0.001
IL-6 pg/ml 13/25(52%) 4.53 (5.89 to 1.73) p Z 0.001
POEMS Z polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes; IQR Z Interquartile range;
aPBSCTZ autologous peripheral blood stem cell transplantation; FEV1Z forced expiratory volume in 1 s; FVCZ forced vital capacity;
TLC Z total lung capacity; DLCO Z diffusion capacity of the lung for carbon monoxide; MIP Z maximum inspiratory pressure;
MEP Z maximum expiratory pressure; RV Z residual volume; RVSP Z right ventricular systolic pressure; VEGF Z vascular endothelial
growth factor; IL-6 Z interleukin-6.
126 S. Chandrashekaran et al.Respiratory failure and survival
Thirteen patients required an intensive care unit stay in the
90-day period following aPBSCT (median length of stay four
days). Of these, five patients required vasopressor use. Five
patients required intubation and mechanical ventilation
(median duration of eleven days) and three of those pa-
tients required non-invasive positive pressure ventilator
(median duration of five days). Patients with respiratory
failure did not have other known pre-existing lung disease
although two were smokers. All five had an abnormal DLCO
at transplant (median 64% predicted). Median MIP and MEP
were 67% and 51% predicted respectively; four out of five
with respiratory failure had abnormal respiratory muscle
function. Three patients had abnormal FEV1 and FVC; me-
dian FEV1 and FVC for those with respiratory failure were
67% and 73% predicted respectively. Only one patient had
an abnormal TLC (median 90% predicted for respiratory
failure subset). There was no association between respira-
tory failure and abnormal DLCO (pZ 0.29), abnormal RVSP
(p Z 0.8), history of smoking (P Z 0.65), abnormal FEV1Table 4 Changes in test parameters in the long term follow up
Parameter Immediate post-aPBSCT
median (IQR)
Long term follo
after aPBSCT
median (IQR)
FEV1% predicted 88 (77.5e97) 91 (79e98)
FVC % predicted 93 (78.75e102.25) 91(74.75e102.5
TLC % 98.5 (89.25e107) 99 (89.5e111)
DLCO % 80.50 (69e86.25) 83.5 (73.5e89.
MIP % 84 (74.5e104) 93 (72e106)
MEP % 72 (60.25e80.25) 75 (63e94)(p Z 0.5), abnormal FVC (p Z 0.28), abnormal TLC
(p Z 0.74), or abnormal respiratory muscle strength
(pZ 0.23). Improvements in pulmonary function tests were
not different in those with respiratory failure versus those
without: FEV1 (p Z 0.8), FVC (p Z 0.31), TLC (p Z 0.27),
MIP (p Z 0.98), DLCO (p Z 0.7), and MEP (p Z 0.58).
There was one death 115 days after aPBSCT; cause of
death was not determined.
Radiological changes
Patients had an improvement in radiologic abnormalities
following aPBSCT (see example Fig. 1A and B). Forty-seven
percent of patients had an abnormal CXR prior to aPBSCT
(NZ 51). Following aPBSCT, the number of patients with a
normal CXR increased (pZ 0.02; NZ 39 patients with CXR)
with a decrease in the number with infiltrates on CXR
(p Z 0.002). Likewise the number of patients with normal
chest CTs increased (p Z 0.008; N Z 21 imaged) with a
decrease in the number of infiltrates on chest CT
(p Z 0.02). Thirteen patients prior to transplant had.
w up Absolute median difference
immediate post vs longterm
follow up after aPBSCT (IQR)
Wilcoxon signed
rank test p-value
1 (1.75 e 6.5) p Z 0.08
) 1.5 (-1 e 5.75) p Z 0.03
2 (1.5 e 5.5) p Z 0.072
5) 4 (0.25e11) p Z 0.0006
6 (-8 e 19) p Z 0.034
6 (-5 e 15) p Z 0.076
Figure 1 A: Chest X-ray in POEMS syndrome patient before
aPBSCT. Note right-sided pleural effusion, low lung volumes,
and infiltrates. B: Same patient’s chest X-ray three months
after aPBSCT demonstrating resolution of abnormal findings.
Pulmonary morbidity improves after autologous stem cell transplantation 127pleural effusions by CXR or CT chest with only four having
effusions following aPBSCT (11 patients had resolution of
effusion; 2 patients had persistent effusion; 2 patients had
new effusion).Discussion
We are the first to demonstrate a statistically significant
improvement in pulmonary function test data and RVSP in
POEMS syndrome patients following aPBSCT. We are also
the first to demonstrate lasting improvement in PFT mea-
sures over 2 years following aPBSCT.Pulmonary function test
We previously demonstrated that pulmonary manifestations
were common in patients with POEMS syndrome and
included pulmonary hypertension, restrictive lung disease,
respiratory muscle weakness, and an isolated decreased
DLCO [1]. Prior preliminary evidence suggested that the
PFT abnormalities may be reversible. For example, one
patient with impaired vital capacity improved following
successful treatment of the plasma cell disorder with
Tamoxifen [26]. In another report, three patients demon-
strated improvement in PFTs following aPBSCT [7]. Our
study confirms both statistically and clinically significant
improvements in pulmonary function tests following
aPBSCT. These improvements include spirometry, lung
volumes (except residual volumes), DLCO, and respiratory
muscle function. It was hypothesized that the pulmonary
function tests improvements may be explained by changes
in edema; however, no significant changes in weight were
seen following aPBSCT which makes this theory less likely
(Table 2). However, absence of weight changes may not
rule out improvements in extra-vascular volume overload.
Interestingly eleven of thirteen patients did show resolu-
tion of pleural effusions following aPBSCT. Given the
improvement in respiratory muscle strength, FVC and RV/
TLC it is likely that improvement in neurologic weakness
accounts for some of the improvement in pulmonary func-
tion testing. Dramatic improvements in neurologic mani-
festations of POEMS syndrome has been reported previously
following treatment with lenalidomide [27]. Neurologic
weakness may also cause atelectasis which can lead to a
diminished DLCO. Improvement in atelectasis associated
with neurologic improvement may explain some of the
improvement in DLCO. In addition, a prior study found that
96% of POEMS syndrome patients with pulmonary hyper-
tension had an abnormal DLCO [3]. We did find that an
abnormal DLCO was significantly associated with an
abnormal RVSP (p Z 0.0034). Improvement in RVSP may
explain some of the DLCO improvement.
The TLC, MEP, and FEV1 measurements at a median of
26.5 months following aPBSCT supported a persistent
change. Interestingly DLCO, MIP and FVC at a median of
26.5 months continued to demonstrate small but statisti-
cally significant continued improvement. This finding is
encouraging to patients and clinicians deciding to pursue
aPBSCT for POEMS syndrome in the face of pulmonary
impairment.Pulmonary hypertension
Pulmonary hypertension is a known complication of POEMS
syndrome [28e30]. In fact, our previous study demon-
strated pulmonary hypertension as high as 48% in the pa-
tients screened with ECHO [1]. Prior reports have
demonstrated improvement in pulmonary hypertension
following treatment with steroids (intravenous or oral) with
or without plasmapheresis, mycophenolate mofetil or
thiamine [3,8,12,13,28,31,32]. Pulmonary hypertension has
been proposed to be caused by elevated cytokines in POEMS
syndrome [11]. Interestingly, bevacizumab (humanized
monoclonal anti-VEGF antibody) improved pulmonary
128 S. Chandrashekaran et al.hypertension in a patient with POEMS syndrome and pul-
monary hypertension [33,34]. However, improvement in
POEMS syndrome with bevacizumab appears to be incon-
sistent based on available data [35]. Our series demon-
strated 58% of the POEMS syndrome patients who
underwent ECHO had an elevated RVSP. Following aPBSCT
patients had a statistically significant decline in RVSP.
However, our analysis did not demonstrate any significant
correlation between abnormal RVSP and IL-6 and VEGF
levels (pZ 0.59 and pZ 0.22 respectively). Due to a small
number of longer term follow-up ECHOs the trajectory of
improvement in RVSP cannot be further delineated in this
cohort.
Chest imaging
Abnormalities in chest imaging were common in POEMS
syndrome patients but improved following aPBSCT.
aPBSCT pulmonary mortality and critical illness
It is well known that aPBSCT is accompanied by risks
including respiratory failure and death. ICU and early
deaths were previously demonstrated to be due to peri-
engraftment syndrome [36]. In our study several patients
required either invasive or non-invasive mechanical venti-
lation and there was one death as previously reported. [7].
Cytokines
The etiology of POEMS syndrome is unclear but could be
related to several cytokines produced by the plasma cells.
Prior reports hypothesize that cytokines are responsible for
pulmonary hypertension and other manifestations of POEMS
syndrome such as edema [11,37]. Elevated levels of VEGF
and IL-6 have been reported in active POEMS syndrome with
decreased levels following treatment [37e45]. In our study
we found that VEGF and IL-6 levels were elevated at
baseline and decreased following aPBSCT however no cor-
relation was found between these cytokines and abnormal
RVSP.
Limitations
Our study has limitations. It is a retrospective cohort study
therefore timing of tests were not standardized by proto-
col. Due to the small number of patients with blood gas
data obtained pre-transplant, change in the partial pres-
sure of oxygen or carbon dioxide could not be analyzed in
this cohort. With respect to PFTs, however, this limitation is
somewhat ameliorated by the narrow time range that
follow-up PFTs occurred in and the availability of most tests
of interest in our patients. In addition, our study can mainly
be applied to patients with mild to moderate lung disease.
Only four patients had severe impairment of DLCO (DLCO
<40% predicted) and only one patient had severe impair-
ment of FEV1 (FEV1 <40% predicted). Further study is
needed to determine if POEMS syndrome patients with se-
vere impairment in lung function have similar recovery in
lung function following aPBSCT. Further our data on pul-
monary hypertension is limited because pulmonary pressurewas estimated by echocardiogram not measured by right
heart catheterization. This limitation is consistent with
prior reports as minimal right heart catheterization data is
reported in the literature with most prior reports relying on
ECHO estimations [1,3]. Finally, RVSP measurements after
aPBSCT were available only for fourteen patients. Never-
theless, our study demonstrated modest and statistically
significant improvement in right ventricular systolic pres-
sure by echocardiogram.
Conclusions
In summary, patients with POEMS syndrome should be
evaluated for PFT, imaging and RVSP abnormalities as such
abnormalities are common in POEMS syndrome. Pulmonary
morbidity in POEMS syndrome improves with aPBSCT
including improvements in imaging, spirometry, TLC and
RV/TLC, respiratory muscle pressures, and RVSP, but does
carry risks of respiratory failure and death following
transplant (which is minimized if one is attuned to and
ready to treat engraftment syndrome). Once improved
pulmonary function test improvements appear stable
(FEV1, MEP, and TLC) or slightly improved (DLCO, MIP, and
FVC) with long-term follow-up. Therefore, mild to moder-
ate pulmonary function test impairments should not be
considered a contraindication to aPBSCT.
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IQRZ interquartile range; aPBSCTZ autologous peripheral
blood stem cell transplantation; FEV1 Z forced expiratory
volume in 1 s; FVC Z forced vital capacity; TLC Z total
lung capacity; DLCO Z diffusion capacity of the lung for
carbon monoxide; MIP Z maximum inspiratory pressure;
MEP Z maximum expiratory pressure;
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